Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
36 participants
INTERVENTIONAL
2023-02-06
2023-12-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Evaluation of Sodium Hyaluronate 32mg/ml in Improving Facial Skin Dryness and Dullness
NCT06914583
Evaluation of the Effects of an Oral Supplementation Containing Hyaluronic Acid
NCT06774742
The Effect of Peroral Sodium Hyaluronate on the Skin
NCT07065110
Evaluation of the Anti-aging Efficacy of Two Dietary Supplements
NCT06032598
Efficacy Study of Oral Collagen Peptide on Skin Condition Improvement
NCT06847035
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hyaluronic Acid 150 mg
Take 150 mg/day of hyaluronic acid.
Hyaluronic acid 75 mg/capsule
Take 2 capsules per day at any time.
Hyaluronic Acid 100 mg
Take 100 mg/day of hyaluronic acid.
Hyaluronic acid 50 mg/capsule
Take 2 capsules per day at any time.
Placebo
Take 0 mg/day of hyaluronic acid.
Placebo
Take 2 capsules per day at any time.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hyaluronic acid 75 mg/capsule
Take 2 capsules per day at any time.
Hyaluronic acid 50 mg/capsule
Take 2 capsules per day at any time.
Placebo
Take 2 capsules per day at any time.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Healthy individuals with no chronic physical diseases, including skin diseases.
3. Person with sagging, dry, or flaky skin.
4. Person who have been fully informed of the purpose and content of the study, have the capacity to consent, understand it well, and voluntarily volunteer to participate in the study, and are able to consent to participation in the study in writing.
5. Person who be able to come to the study site on the designated examination date and undergo the examination.
6. Person who are deemed suitable by the investigator to participate in the study.
Exclusion Criteria
2. Patients with skin disease symptoms such as atopic dermatitis.
3. Patients who have scars or inflammation on the evaluation site.
4. Patients who have taken or applied drugs in the past month for the purpose of treatment of the disease (excluding those who have taken drugs for headache, menstrual cramps, common cold, etc.).
5. Patients with a history or current history of serious disorders of the liver, kidney, heart, lungs, blood, etc.
6. Patients with comorbidities and serious history of gastrointestinal disorders.
7. Patients with severe anemia.
8. BMI of 30.0 kg/m2 or more.
9. Person who are allergic to any ingredient in the test food or who are at risk of developing serious allergic reactions to any other food or drug.
10. person is currently, or within the past 3 months has been, or will be during the study period, a habitual consumer of functional foods, health foods, or supplements containing active ingredients similar to those in the test food.
11. Currently, and within the past 3 months, those who have or will take functional foods, health foods, or supplements that claim to improve skin on a regular basis during the study period (consumption for the purpose of maintaining good health is acceptable).
12. Currently, or within the past 3 months, those who have a habit of continuously taking or applying drugs that are claimed to improve the skin.
13. Pregnant, lactating, or of child-bearing potential.
14. Patients whose daily alcohol consumption exceeds an average of 60g/day of pure alcohol equivalent.
15. Patient with mental disorders.
16. Persons with a smoking habit.
17. Those who may change their lifestyle during the examination period (e.g., work at night, travel for long periods of time, etc.).
18. Patient who may develop seasonal allergic symptoms such as hay fever and may use medicines during the study period.
19. Persons who will be extremely neglectful of their skin care.
20. Those who intentionally cannot refrain from being exposed to direct sunlight, such as sunburn, during the examination period.
21. Person with a history of cosmetic procedures or treatments on the evaluation site within the past 6 months.
22. Person with currently participating in another human clinical trial, or who have not yet completed 3 months of participation in another human clinical trial.
23. Person who are judged by the investigator to be inappropriate for this study.
30 Years
60 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bloomage Biotechnology Corp., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Atsushi Nakajima, MD
Role: STUDY_CHAIR
Ueno Asagao Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ueno Asagao Clinic
Taito-ku, Tokyo, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HR-2023-BMB01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.